Banafshé Larijani is the Director of the Centre for Therapeutic Innovation (CTI). Her laboratory, Cell Biophysics, is currently bridged between the Department of Pharmacy and Pharmacology at University of Bath and The Biophysics Institute (Instituto Biofisika) at the University of the Basque Country, Spain.  Since 2002 she was Head of Cell Biophysics Laboratory at Cancer Research UK, was appointed Senior Scientist in 2012 and in 2014 was awarded an Ikerbasque Research Professorship where she moved her laboratory to the Biophysics Institute and the Research Centre for Experimental Marine Biology and Biotechnology (PiE) Bilbao, Spain. She holds adjunct professorships with Stony Brooks University NY and University of Massachusetts, Amherst MA, (USA).

Professor Larijani's laboratory is a cutting edge cross-disciplinary platform, which draws upon the physical sciences to develop novel avenues for investigation of biological processes in signalling. Her laboratory has led to paving a unique path by investigating the role of phosphoinositides and their metabolites, both as second messengers and as modulators of membrane morphology. The outcomes of her fundamental research involving the application of quantitative imaging (FRET-FLIM) for investigating molecular mechanisms of phosphoinositide-modifying and phosphoinositide-dependant enzymes have resulted in their application to various clinical objectives.

While in the  Basque Country (2014) her laboratory and her new cancer diagnostic/prognostic company, FASTBASE SOLUTIONS Ltd, have been awarded 6 peer-reviewed grants. Prior to that all laboratory funding was based on core-funding at Cancer Research UK. Since 2002 she has more than published 90 primary research articles in the area of nuclear envelope biogenesis, lipid signalling and cancer biology and has over 2600 citations.